Inhibition of aquaporin-1 prevents myocardial remodeling by blocking the transmembrane transport of hydrogen peroxide.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
07 10 2020
Historique:
received: 30 05 2019
revised: 24 12 2019
accepted: 31 08 2020
entrez: 8 10 2020
pubmed: 9 10 2020
medline: 24 6 2021
Statut: ppublish

Résumé

Pathological remodeling of the myocardium has long been known to involve oxidant signaling, but strategies using systemic antioxidants have generally failed to prevent it. We sought to identify key regulators of oxidant-mediated cardiac hypertrophy amenable to targeted pharmacological therapy. Specific isoforms of the aquaporin water channels have been implicated in oxidant sensing, but their role in heart muscle is unknown. RNA sequencing from human cardiac myocytes revealed that the archetypal

Identifiants

pubmed: 33028705
pii: 12/564/eaay2176
doi: 10.1126/scitranslmed.aay2176
pii:
doi:

Substances chimiques

Aquaporin 1 146410-94-8
Hydrogen Peroxide BBX060AN9V

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Virginie Montiel (V)

Institute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Ramona Bella (R)

Institute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Lauriane Y M Michel (LYM)

Institute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Hrag Esfahani (H)

Institute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Delphine De Mulder (D)

Institute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Emma L Robinson (EL)

Laboratory of Experimental Cardiology, Department of Cardiovascular Sciences, KULeuven, 3000 Leuven, Belgium.

Jean-Philippe Deglasse (JP)

Institute of Experimental and Clinical Research (IREC), Endocrinology, Diabetes and Nutrition (EDIN), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Malte Tiburcy (M)

Institute of Pharmacology and Toxicology, University Medical Center Göttingen, 37075 Göttingen, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Göttingen, 37075 Göttingen, Germany.

Pak Hin Chow (PH)

Adelaide Medical School, University of Adelaide, Adelaide, SA 5000, Australia.

Jean-Christophe Jonas (JC)

Institute of Experimental and Clinical Research (IREC), Endocrinology, Diabetes and Nutrition (EDIN), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Patrick Gilon (P)

Institute of Experimental and Clinical Research (IREC), Endocrinology, Diabetes and Nutrition (EDIN), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Benjamin Steinhorn (B)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 2115, USA.

Thomas Michel (T)

Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 2115, USA.

Christophe Beauloye (C)

Institute of Experimental and Clinical Research (IREC), Pole of Cardiovascular Research (CARD), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Luc Bertrand (L)

Institute of Experimental and Clinical Research (IREC), Pole of Cardiovascular Research (CARD), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Charlotte Farah (C)

Institute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Flavia Dei Zotti (F)

Institute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Huguette Debaix (H)

Institute of Experimental and Clinical Research (IREC), Nephrology (NEFR), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
Institute of Physiology, University of Zürich, CH 8057 Zürich, Switzerland.

Caroline Bouzin (C)

2IP-IREC Imaging Platform, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Davide Brusa (D)

Flow Cytometry Platform, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Sandrine Horman (S)

Institute of Experimental and Clinical Research (IREC), Pole of Cardiovascular Research (CARD), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Jean-Louis Vanoverschelde (JL)

Institute of Experimental and Clinical Research (IREC), Pole of Cardiovascular Research (CARD), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.

Olaf Bergmann (O)

Center for Regenerative Therapies Dresden, Technische Universität Dresden, 01062 Dresden, Germany.
Department of Cell and Molecular Biology, Karolinska Institutet, 171 77 Stockholm, Sweden.

Dimitri Gilis (D)

Computational Biology and Bioinformatics (3BIO-BioInfo), Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium.

Marianne Rooman (M)

Computational Biology and Bioinformatics (3BIO-BioInfo), Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium.

Alessandra Ghigo (A)

Molecular Biotechnology Center, Università di Torino, 10124 Torino, Italy.

Simonetta Geninatti-Crich (S)

Molecular Biotechnology and Health Sciences, Università di Torino, 10124 Torino, Italy.

Andrea Yool (A)

Adelaide Medical School, University of Adelaide, Adelaide, SA 5000, Australia.

Wolfram H Zimmermann (WH)

Institute of Pharmacology and Toxicology, University Medical Center Göttingen, 37075 Göttingen, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Göttingen, 37075 Göttingen, Germany.
Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells" (MBExC), University of Göttingen, 37075 Göttingen, Germany.

H Llewelyn Roderick (HL)

Laboratory of Experimental Cardiology, Department of Cardiovascular Sciences, KULeuven, 3000 Leuven, Belgium.

Olivier Devuyst (O)

Institute of Experimental and Clinical Research (IREC), Nephrology (NEFR), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
Institute of Physiology, University of Zürich, CH 8057 Zürich, Switzerland.

Jean-Luc Balligand (JL)

Institute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St Luc and Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium. jl.balligand@uclouvain.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH